ArticleBMC cancer2017

Cost-effectiveness analysis of the introduction of S-1 therapy for first-line metastatic breast cancer treatment in Japan: results from the randomized phase III SELECT BC trial.

Takeru Shiroiwa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.